On May 31, 2018 Cancer Research UK and Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, reported a poster presentation at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) held from June 1 – June 5, 2018 in Chicago, Ill (Press release, Bicycle Therapeutics, 31 31, 2018, View Source [SID1234527010]). The poster describes their ongoing phase I/IIa clinical trial of BT1718 in patients with advanced solid tumours, which is the first clinical study of a bicyclic peptide.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentation, which will be given by Dr. Udai Banerji, Principal Investigator for the Phase I trial, are as follows:
A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Drug Conjugate) given intravenously in patients with advanced solid tumours
Session Title: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Time: June 4, 2018, 8:00 – 11:30 a.m. CT
ABOUT BT1718
BT1718 is a first-in-class Bicycle Toxin Conjugate being developed by Bicycle Therapeutics that targets Membrane Type 1 Matrix Metalloproteinase (MT1-MMP), also known as MMP-14. This target has an established role in cell invasion and metastasis, is linked to poor outcomes and is over expressed in many solid tumours. In preclinical models, BT1718 has demonstrated promising target-dependent efficacy and only a subset of the toxicities typically associated with other highly potent cancer treatments.
Cancer Research UK’s Centre for Drug Development (CDD) is sponsoring a Phase I/IIa study of BT1718 that started in February 2018 with patients currently progressing through dose escalation cohorts. The trial is co-managed by Cancer Research UK and Bicycle Therapeutics. Under the terms of the agreement, Bicycle retains the right to further advance the BT1718 program, at which point an undisclosed payment split between cash and equity, success-based milestones and royalty payments would be made to Cancer Research UK.